Bobby,
Short answer: no BIEL shareholder (publicly, at least) has provided a confirmed, on-the-record reason for the manufacturing shift from CICD (China) to Well-Life (Taiwan). Everything circulating right now is informed speculation, but some of that speculation is very reasonable.
1. Lower product cost?
Possible, but not the strongest driver.
Taiwan manufacturing is not always cheaper than China on a pure unit-cost basis.
However, Taiwan can be more cost-predictable, with:
Better IP protection
Fewer surprise shutdowns
Higher consistency and yields
So while unit cost might not be lower, total landed cost + risk may be.
2. New or potential China tariffs?
This is a very strong possibility.
The U.S. has:
Existing tariffs on Chinese medical devices/components
Ongoing political pressure to expand them
Moving manufacturing before a tariff change:
Protects margins
Improves investor optics
Reduces supply-chain shock risk
Many companies are quietly doing the same thing right now.
3. Involvement with Electrome?
Very plausible, especially for future products.
If Electrome is involved (now or soon), they would likely require:
A manufacturer that meets higher clinical, FDA, and quality-system expectations
Experience supporting:
Clinical trials
Human-use neurotech
FDA design controls
Well-Life:
Has stronger medical-grade credibility
Is more aligned with neuromodulation / clinical devices than CICD
Even if Electrome isn’t officially announced, pre-alignment makes strategic sense.
4. Requirement by Electrome?
Could be indirect rather than explicit.
Electrome might not say:
“You must use this factory”
But they would say:
“The manufacturing partner must meet X, Y, Z standards”
Which could naturally:
Eliminate CICD
Elevate Well-Life (or similar Taiwanese firms)
Market Data 
Markets 
